Celerion has announced its achievement of a full Association for the Accreditation of Human Research Protection Programs (AAHRPP) reaccreditation for five years by the Council on Accreditation of AAHRPP.
Celerion is the only CRO headquartered in the USA to hold this distinguished accreditation.
This prestigious recognition underscores Celerion's unwavering dedication to maintaining the highest ethical standards, safeguarding participant welfare and fostering excellence in clinical research.
AAHRPP accreditation is a coveted distinction in the research industry, signifying that an organisation upholds rigorous standards for human research protection.
By achieving this reaccreditation, Celerion strengthens its position as an industry leader and its ongoing commitment to advancing groundbreaking clinical studies safely and ethically.
"This milestone represents the hard work and dedication of our entire team," said Phil Bach, Celerion’s Executive Vice President of Global Clinical Research.
"We are deeply committed to upholding participant safety and the highest ethical standards in our research."
"Earning AAHRPP reaccreditation for five years reflects our steadfast focus on setting the benchmark for clinical research excellence and integrity."
"We are honoured to receive this recognition and remain focused on making meaningful contributions to the field of clinical development."
The AAHRPP accreditation process is rigorous, requiring a comprehensive evaluation of an organisation’s policies, practices and commitment to continuous improvement in human research protection.
This achievement reinforces Celerion’s capability to manage complex clinical programmes whilst prioritising the well-being of participants — an essential element of ethical research practices.
With more than 50 years of experience in clinical research, Celerion has earned a global reputation for innovation and leadership.
This reaccreditation not only validates the company’s dedication to regulatory compliance but also sets it apart as a trusted partner for sponsors seeking to conduct high-quality research.